intellikineintellikine

joins
the Takeda Family of Companies

In December 2011, we welcomed Intellikine into the Takeda Family of Companies.

Millennium: The Takeda Oncology Company, Takeda’s business unit responsible for global oncology strategy and development, has taken over global development responsibility for the Intellikine pipeline, including the molecules INK128 and INK1117. The Intellikine clinical-stage discovery of small molecule drugs targeting signal transduction networks, combined with our innovative development strategy, robust pipeline and global assets, strengthens our singular focus and resolve to improve the treatment of cancer.